Global perspectives on CYP2D6 associations with primaquine metabolism and Plasmodium vivax radical cure

Jasmine M Olvany; Scott M Williams; Peter A Zimmerman

doi:10.3389/fphar.2022.752314

Global perspectives on CYP2D6 associations with primaquine metabolism and Plasmodium vivax radical cure

Front Pharmacol. 2022 Nov 15:13:752314. doi: 10.3389/fphar.2022.752314. eCollection 2022.

Authors

Jasmine M Olvany^{1

2

3}, Scott M Williams^{2

3}, Peter A Zimmerman^{1

4}

Affiliations

¹ The Center for Global Health and Diseases, Pathology Department, Case Western Reserve University, Cleveland, OH, United States.
² Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
³ Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
⁴ Master of Public Health Program, Case Western Reserve University, Cleveland, OH, United States.

Abstract

Clinical trial and individual patient treatment outcomes have produced accumulating evidence that effective primaquine (PQ) treatment of Plasmodium vivax and P. ovale liver stage hypnozoites is associated with genetic variation in the human cytochrome P450 gene, CYP2D6. Successful PQ treatment of individual and population-wide infections by the Plasmodium species that generate these dormant liver stage forms is likely to be necessary to reach elimination of malaria caused by these parasites globally. Optimizing safe and effective PQ treatment will require coordination of efforts between the malaria and pharmacogenomics research communities.

Keywords: CYP2D6; activity score; hypnozoite; malaria; primaquine.

Publication types

Review